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Glucose Tolerance and Cardiovascular Mortality
Comparison of Fasting and 2-Hour Diagnostic Criteria
The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group
Background: New diagnostic criteria for diabetes based
on fasting blood glucose (FBG) level were approved by
the American Diabetes Association. The impact of using
FBG only has not been evaluated thoroughly. The fast-
ing and the 2-hour glucose (2h-BG) criteria were com-
pared with regard to the prediction of mortality.
Methods: Existing baseline data on glucose level at fast-
ing and 2 hours after a 75-g oral glucose tolerance test
from 10 prospective European cohort studies including
15388 men and 7126 women aged 30 to 89 years, with
a median follow-up of 8.8 years, were analyzed. Haz-
ards ratios for death from all causes, cardiovascular dis-
ease, coronary heart disease, and stroke were estimated.
Results: Multivariate Cox regression analyses showed
that the inclusion of FBG did not add significant infor-
mation on the prediction of 2h-BG alone (P..10 for vari-
ous causes), whereas the addition of 2h-BG to FBG cri-
teria significantly improved the prediction (P,.001 for
all causes and P,.005 for cardiovascular disease). In a
model including FBG and 2h-BG simultaneously, haz-
ards ratios (95% confidence intervals) in subjects with
diabetes on 2h-BG were 1.73 (1.45-2.06) for all causes,
1.40 (1.02-1.92) for cardiovascular disease, 1.56 (1.03-
2.36) for coronary heart disease, and 1.29 (0.66-2.54) for
stroke mortality, compared with the normal 2h-BG group.
Compared with the normal FBG group, the correspond-
ing hazards ratios in subjects with diabetes on FBG were
1.21 (1.01-1.44), 1.20 (0.88-1.64), 1.09 (0.71-1.67), and
1.64 (0.88-3.07), respectively. The largest number of ex-
cess deaths was observed in subjects who had impaired
glucose tolerance but normal FBG levels.
Conclusion: The 2h-BG is a better predictor of deaths
from all causes and cardiovascular disease than is FBG.
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N EW DIAGNOSTIC criteriafor diabetes mellitusbased on the fastingblood glucose levelalone (fasting plasma
glucose $7.0 mmol/L [126 mg/dL]) were
approved by the American Diabetes As-
sociation (ADA) Expert Group.1 For epi-
demiological purposes, the ADA recom-
mended the use of fasting glucose level
alone and did not recommend the 2-hour
75-g oral glucose tolerance test. The choice
of the cutoff point was based on bimodali-
ties in the fasting glucose distribution1 and
on the association between fasting glu-
cose level and risk of diabetic retinopa-
thy. The World Health Organization)
adopted the same fasting glucose level as
the ADA, but retained the use of the 2-hour
glucose tolerance test for the diagnosis of
diabetes in population studies.2 The 2-hour
75-g oral glucose tolerance test has been
the international standard for diabetes di-
agnosis since 19853 and the basis of much
epidemiological data in the medical lit-
erature about risks of complications as-
sociated with diabetes.
To evaluate the prognostic impact of
the new fasting glucose criteria, the
DECODE (Diabetes Epidemiology: Col-
laborative analysis Of Diagnostic criteria
in Europe) Study was initiated. We have
previously reported that there was a high
degree of disagreement in the fasting and
2-hour glucose classifications in Euro-
pean populations.4 Among subjects with
diabetes diagnosed by a fasting glucose
level of 7.0 mmol/L or more, only 46% also
had 2-hour glucose level of 11.1 mmol/L
or more ($200 mg/dL), the 2-hour glu-
cose diagnostic criterion for diabetes.2,3
Furthermore, analyses of the DECODE da-
tabase showed that abnormalities in 2-hour
glucose levels were better predictors of all-
cause mortality than fasting glucose alone.5
A high 2-hour glucose concentration was
found to be associated with an increased
risk of death, independent of the level of
fasting blood glucose, whereas mortality
associated with the fasting glucose con-
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centration depended on the level of 2-hour glucose, in
all categories of fasting glucose.
Because most patients with type 2 diabetes melli-
tus die of cardiovascular diseases (CVD) and not of mi-
crovascular complications, cardiovascular mortality and
morbidity should be considered in defining the diagnos-
tic criteria for diabetes. Herein we report on cardiovas-
cular deaths as well as all-cause deaths in the DECODE
Study population.
RESULTS
The number of men and women and the percentage of
deaths due to cardiovascular and all causes, according
to the fasting and the 2-hour glucose criteria, by
DECODE study centers, are shown in Table 1and
Table 2, respectively, for subjects not previously known
as diabetic. Age-standardized death rates from all causes
and cardiovascular causes were higher in diabetic sub-
jects than in those not meeting diabetic criteria (Tables
1 and 2). Increased mortality was also observed in sub-
jects with IGT (Table 2), whereas there was no differ-
ence between subjects with IFG and those with normal
fasting glucose (Table 1). Mortality from the various causes
was higher in men than in women (Tables 1 and 2).
Subjects who had 2-hour glucose levels of 11.1
mmol/L or more (whole blood, $10.0 mmol/L) and fast-
ing glucose levels less than 7.0 mmol/L (whole blood,
,6.1mmol/L) were older and had higher serum choles-
terol levels than those whose fasting glucose levels were
$7.0 mmol/L (whole blood, $6.1 mmol/L) and 2-hour
glucose levels less than 11.1 mmol/L (whole blood, ,10.0
mmol/L). The latter group was more obese (Table 3).
Multivariate-adjusted Cox proportional hazards
model analyses showed that diabetic subjects by either
the fasting or the 2-hour glucose criteria had an in-
PARTICIPANTS AND METHODS
PARTICIPANTS AND METHODS
The study populations and the methods used to recruit the
participants have been reported previously.4-6 Briefly, re-
searchers in Europe who had performed population-based
studies or large studies in occupational groups using the stan-
dard 2-hour 75-g oral glucose tolerance test were invited to
participate in the DECODE Study. Individual data on fast-
ing and 2-hour glucose concentrations and several other vari-
ables were sent to the Diabetes and Genetic Epidemiology
Unit of the National Public Health Institute in Helsinki, Fin-
land, for collaborative data analyses. In this article, only the
studies with prospective data on cause-specific mortality and
all required confounding variables (cholesterol, blood pres-
sure, smoking habits, and body mass index) were included.
Atotalof13centersprovidedcause-specificmortalitydata
for theDECODEStudy,10ofwhichprovideddatawithall the
covariates required. All 10 studies included men (n=15388)
and6includedwomen(n=7126).Amongthe22514subjects,
aged 30 to 89 years, 796 subjects were previously diagnosed
as having diabetes. For the other 21718 subjects who had no
previous history of diabetes, the median duration of follow-
up was 8.8 years (5.8 and 20.6 years for the 25th and the 75th
quartiles, respectively), and208203person-years inmenand
52536 person-years in women were accumulated.
Subjects who had not previously been diagnosed as
having diabetes were classified according to the following
criteria: (1) 2-hour glucose criteria alone: 2-hour plasma glu-
cose concentrations of 11.1 mmol/L or more ($10.0 mmol/L
[$180 mg/dL] for whole blood) for diabetes, 7.8 to 11.0
mmol/L (140-198 mg/dL) (6.7-9.9 mmol/L [121-178 mg/
dL] for whole blood) for impaired glucose tolerance (IGT),
and less than 7.8 mmol/L (,140 mg/dL) (,6.7 mmol/L
[,121 mg/dL] for whole blood) for normal glucose toler-
ance; and (2) fasting glucose criteria alone: fasting plasma
glucose level of 7.0 mmol/L or more ($126 mg/dL) ($6.1
mmol/L [$110 mg/dL] for whole blood) for diabetes, 6.1
to 6.9 mmol/L (110-124 mg/dL) (5.6-6.0 mmol/L [101-
108 mg/dL] for whole blood) for impaired fasting glucose
(IFG), and less than 6.1 mmol/L (,110 mg/dL) (,5.6
mmol/L [,101 mg/dL] for whole blood) for normal fast-
ing glucose.
Vital status information was recorded for each of the
subjects attending the baseline examination in all of the stud-
ies. Subjects who emigrated, for whom the vital status could
not be confirmed, were treated as censored at the time of
emigration. Follow-up was complete, ranging from 95.2%
in the Paris Prospective Study to 100% in most of the other
studies.5 Causes of death were classified using the Interna-
tional Classification of Diseases, Eighth and Ninth Revision,
codes 401-448 (CVD), 410-414 (coronary heart disease
[CHD]), and 430-438 (stroke).
Body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters. Sub-
jects were classified as nonsmokers, ex-smokers, and cur-
rent smokers.
STATISTICAL ANALYSIS
Age-standardized mortality was calculated using 10-year
age groups, separately for men and women, and direct stan-
dardization for a European standard population.7 Age- and
center-standardized means were compared using analysis
of variance according to the diabetic status defined by the
fasting and by the 2-hour glucose criteria. Hazard ratios of
cause-specific and all-cause mortality were estimated for
the various glucose categories, using the Cox propor-
tional hazards model, and adjusting for age, center, BMI,
systolic blood pressure, serum cholesterol level, smoking
status, and sex if men and women were combined. Results
are presented as mortality hazards ratios and 95% confi-
dence intervals, with respect to the given reference groups.
Cumulative mortality curves were estimated by the same
Cox proportional hazards model. Nested models were com-
pared using a x2 log-likelihood ratio test to determine
whether men and women had significantly different haz-
ards ratios and whether the fasting glucose criteria or the
2-hour glucose criteria were independent of each other in
predicting mortality from cardiovascular causes and from
all causes. The absolute number of excess deaths from all
cardiovascular causes was calculated by comparison with
the group determined to be strictly normal using both the
fasting and the 2-hour glucose criteria.
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creased hazards ratio of death from cardiovascular causes
and from all causes compared with those normal on the
corresponding criteria (Table 4). The hazards ratios for
the various causes of death tended to be higher in dia-
betic women than in diabetic men, but these differences
in hazards ratios were significant only for CHD mortal-
ity (x2=11.57 for fasting glucose criteria and x2=11.35
for 2-hour glucose criteria, 3 df, P,.01). Increased haz-
ards ratios for deaths from all-cause, CVD, and CHD mor-
tality were also observed in subjects with IGT, but not
in subjects with IFG (Table 4). In a model including the
fasting and the 2-hour glucose criteria simultaneously,
the hazards ratios for death from the various causes were
only slightly reduced in individuals with IGT or diabe-
tes for the 2-hour glucose (Table 5), but decreased sig-
nificantly in subjects with IFG and diabetes for the fast-
ing glucose. Comparing nested models, inclusion of the
fasting glucose categories did not significantly improve
the prediction of the 2-hour glucose alone, in contrast,
addition of the 2-hour categories to the fasting glucose
categories significantly improved the prediction (ex-
cept in the case of stroke mortality) (Table 5).
The cumulative hazards curves (Figure 1) further
illustrate the differences between the 2 diagnostic crite-
ria. Previously known diabetic subjects had worse sur-
vival profiles for fatal CVD and CHD events than those
observed in the newly diagnosed diabetic subjects ac-
cording to either the fasting or the 2-hour glucose cri-
teria. The survival curves for known and screened dia-
betic subjects were similar for fatal stroke events and for
all-cause mortality. The subjects with IGT had a sur-
vival profile in between the diabetic and the normal sub-
jects according to the 2-hour glucose criteria and clearly
worse than the normal subjects for fatal cardiovascular
events and for all-cause mortality. The subjects with IFG
had a survival curve similar to that of the subjects nor-
Table 1. Number of Subjects and Percentage of Deaths From Cardiovascular Disease (CVD), Coronary Heart Disease (CHD),
Stroke, and All Causes According to Fasting Glucose Categories, by DECODE Study Centers
in Subjects Not Previously Diagnosed as Diabetic*
Center
Fasting Plasma (Whole Blood) Glucose Category, mmol/L†
Normal Fasting Glucose
,6.1 (5.6)
Impaired Fasting Glucose
6.1-6.9 (5.6-6.0)
Diabetes
$7.0 (6.1)
No. CVD CHD Stroke All No. CVD CHD Stroke All No. CVD CHD Stroke All
Men
Paris Prospective Study,
France
5532 5.7 2.5 1.3 26.4 1129 6.0 2.4 1.3 29.1 237 10.1 3.4 3.4 48.1
FIN MONICA, Finland 1813 4.1 3.3 0.5 8.4 183 2.2 1.6 0.5 3.8 40 7.5 5.0 0.0 10.0
Helsinki Policemen Study,
Finland
1055 18.0 11.5 4.0 36.4 48 27.1 20.8 4.2 47.9 17 41.2 29.4 11.8 64.7
MONICA Study, Northern
Sweden
923 0.9 0.5 0.0 2.5 89 0.0 0.0 0.0 2.2 20 5.0 0.0 0.0 10.0
Hoorn Study, the
Netherlands
880 3.2 0.5 0.7 9.7 155 5.2 1.9 1.3 14.8 63 6.3 0.0 3.2 20.6
Glostrup Study, Denmark 878 17.9 12.6 3.4 39.2 78 10.3 10.3 0.0 23.1 45 20.0 17.8 0.0 40.0
Cremona Study, Italy 670 2.5 0.7 0.3 8.4 47 6.4 0.0 2.1 19.1 17 11.8 0.0 11.8 23.5
Zutphen Study, the
Netherlands
320 10.6 5.3 2.2 22.5 90 12.2 6.7 1.1 27.8 32 6.3 6.3 0.0 31.3
East and west Finland 265 13.2 10.2 2.3 30.6 61 19.7 14.8 3.3 36.1 28 14.3 10.7 3.6 42.9
POL-MONICA, Poland 133 7.5 5.3 0.8 10.5 27 0.0 0.0 0.0 0.0 7 0.0 0.0 0.0 0.0
Total
Unstandardized 12 469 7.0 4.0 1.4 21.4 1907 6.7 3.5 1.3 24.0 506 11.1 5.5 3.0 37.2
Age standardized . . . 7.2 4.3 1.2 19.7 . . . 7.3 4.6 1.0 19.5 . . . 9.0 4.6 2.2 27.5
Women
FIN MONICA, Finland 2268 0.6 0.4 0.2 2.6 98 2.0 1.0 1.0 4.1 27 7.4 7.4 0.0 7.4
MONICA Study, Northern
Sweden
1027 0.1 0.0 0.1 1.1 49 0.0 0.0 0.0 0.0 13 0.0 0.0 0.0 0.0
Hoorn Study, the
Netherlands
1089 1.3 0.0 0.5 5.3 131 1.5 0.0 0.0 9.9 57 1.8 0.0 1.8 10.5
Glostrup Study, Denmark 872 11.6 6.3 3.0 25.6 52 13.5 3.8 7.7 19.2 34 26.5 20.6 5.9 35.3
Cremona Study, Italy 887 1.6 0.3 0.2 4.1 31 0.0 0.0 0.0 3.2 16 0.0 0.0 0.0 12.5
POL-MONICA, Poland 171 0.6 0.0 0.0 2.9 11 0.0 0.0 0.0 0.0 3 0.0 0.0 0.0 0.0
Total
Unstandardized 6314 2.3 1.0 0.6 6.2 372 3.0 0.8 1.3 7.5 150 8.0 6.0 2.0 14.7
Age standardized . . . 3.2‡ 1.2‡ 0.9‡ 7.5‡ . . . 3.0§ 0.4§ 2.2\ 5.8‡ . . . 4.2\ 3.3\ 0.9\ 9.2‡
*DECODE indicates Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe; MONICA, Monitoring of Trends and Determinants
in Cardiovascular Disease.
†To convert glucose to milligrams per deciliter, divide by 0.05551.
‡P,.001, men vs women.
§P,.01, men vs women.
\P..05, men vs women.
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moglycemic on the fasting glucose criteria alone. Over-
all, the cumulative hazard curves were better separated
for the three 2-hour glucose categories than for the 3
fasting glucose categories, indicating that the former
classification provides a better discrimination for car-
diovascular fatal events and for all-cause death.
The highest absolute number of excess cardiovas-
cular deaths attributable to the fasting and the 2-hour glu-
cose criteria was for subjects with IGT, particularly those
who had normal fasting glucose levels (Figure 2).
COMMENT
Diabetes is an important independent risk factor for CVD
mortality.8-15 Hyperglycemia, in the absence of clini-
cally diagnosed diabetes, has also been associated with
an increased risk of CVD and all-cause mortality in some,
but not all studies.8-11,16-38 The lack of adjustment for the
established risk factors, applying unstandardized meth-
ods for the glucose test and the small number of events
obtained during follow-up might have contributed to these
inconsistencies. Our analyses, based on a large Euro-
pean population with more than 260000 person-years
of follow-up, show that asymptomatic diabetes as well
as IGT defined by the 2-hour glucose criteria alone, in-
creased the risk of death from cardiovascular causes and
all causes, independent of other known risk factors and
the level of fasting glucose. In contrast, mortality asso-
ciated with the fasting glucose concentration depended
largely on the level of 2-hour glucose.
This study is a collaborative study based on the
data collected from 10 different centers in different
countries in Europe. There is no uniform approach to
the quality control in the glucose measurements. This
was not possible in such a large collaborative study
based on retrospective data. Also, as in other population
studies, fasting status could not always be assured. It is
possible that failure to report prior energy (calorie)
Table 2. Number of Subjects and Percentage of Deaths From Cardiovascular Disease (CVD), Coronary Heart Disease (CHD),
Stroke, and All Causes According to 2-Hour Glucose Categories, by DECODE Study Centers in Subjects
Not Previously Diagnosed as Diabetic*
Center
2-h Plasma (Whole Blood) Glucose Category, mmol/L†
Normal Glucose Tolerance
,7.8 (6.7)
Impaired Glucose Tolerance
7.8-11.0 (6.7-9.9)
Diabetes
$11.1 (10.0)
No. CVD CHD Stroke All No. CVD CHD Stroke All No. CVD CHD Stroke All
Men
Paris Prospective Study,
France
6102 5.6 2.4 1.3 25.6 638 7.5 3.3 2.2 39.7 158 10.1 3.8 3.2 55.7
FIN MONICA, Finland 1766 3.5 2.8 0.5 7.3 236 7.6 5.5 0.8 11.9 34 8.8 5.9 0.0 17.6
Helsinki Policemen
Study, Finland
1067 18.1 11.7 3.8 36.5 43 32.6 20.9 9.3 53.5 10 30.0 20.0 10.0 60.0
MONICA Study, Northern
Sweden
944 0.8 0.5 0.0 2.6 72 1.4 0.0 0.0 2.8 16 0.0 0.0 0.0 0.0
Hoorn Study, the
Netherlands
938 3.4 0.5 0.9 9.8 107 6.5 1.9 0.9 15.9 53 1.9 0.0 1.9 22.6
Glostrup Study, Denmark 629 19.4 13.7 3.8 44.4 292 14.0 11.0 1.7 26.0 80 13.8 11.3 1.3 31.3
Cremona Study, Italy 657 2.1 0.8 0.2 7.8 61 9.8 0.0 3.3 23.0 16 12.5 0.0 12.5 25.0
Zutphen Study, the
Netherlands
356 11.0 5.6 2.2 23.3 50 6.0 2.0 0.0 26.0 36 13.9 11.1 0.0 30.6
East and west Finland 216 14.8 11.1 3.2 29.6 105 13.3 9.5 1.9 33.3 33 15.2 15.2 0.0 48.5
POL-MONICA, Poland 131 6.1 5.3 0.8 9.2 29 6.9 0.0 0.0 6.9 7 0.0 0.0 0.0 0.0
Total
Unstandardized 12 806 6.7 3.7 1.4 21.0 1633 9.4 5.4 1.8 28.4 443 10.4 6.3 2.3 37.9
Age standardized . . . 7.0 4.2 1.2 19.3 . . . 8.3 4.9 1.4 22.8 . . . 8.1 4.9 1.7 28.2
Women
FIN MONICA, Finland 2047 0.5 0.3 0.1 2.2 304 1.6 1.0 0.3 4.3 42 7.1 4.8 2.4 14.3
MONICA Study, Northern
Sweden
954 0.1 0.0 0.1 0.8 110 0.0 0.0 0.0 1.8 25 0.0 0.0 0.0 4.0
Hoorn Study, the
Netherlands
1066 1.1 0.0 0.5 4.9 153 2.0 0.0 0.0 10.5 58 3.4 0.0 1.7 15.5
Glostrup Study, Denmark 690 10.9 5.7 3.0 24.9 216 13.0 6.5 3.7 24.1 52 26.9 21.2 5.8 40.4
Cremona Study, Italy 813 1.4 0.4 0.2 3.2 91 3.3 0.0 0.0 12.1 30 0.0 0.0 0.0 6.7
POL-MONICA, Poland 129 0.8 0.0 0.0 3.1 50 0.0 0.0 0.0 2.0 6 0.0 0.0 0.0 0.0
Total
Unstandardized 5699 1.9 0.8 0.6 5.4 924 4.2 1.8 1.0 10.3 213 8.9 6.1 2.3 18.3
Age standardized . . . 3.2‡ 1.1‡ 1.1‡ 6.9‡ . . . 3.7‡ 1.2‡ 1.0§ 9.6‡ . . . 5.1§ 3.7§ 1.2§ 11.2‡
*DECODE indicates Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe; MONICA, Monitoring of Trends and Determinants in
Cardiovascular Disease.
†To convert glucose to milligrams per deciliter, divide by 0.05551.
‡P,.001, men vs women.
§P..05, men vs women.
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Table 3. Characteristics of Diabetic Subjects at Baseline According to Fasting and 2-Hour Glucose Criteria
in Subjects Not Previously Diagnosed as Diabetic in the DECODE Study*
Characteristic
Plasma (Whole) Blood Glucose Category, mmol/L†
P
Fasting ,7.0 (6.1)
and 2-h ,11.1 (10.0),
Nondiabetic
(n = 20 707)
Fasting $7.0
and 2-h ,11.1,
Diabetic on Fasting
(n = 355)
Fasting ,7.0
and 2-h $11.1,
Diabetic on 2-h
(n = 355)
Fasting $7.0
and 2-h $11.1,
Diabetic on Both
(n = 301)
Age, y 53 (0.1) 54 (0.5) 56 (0.5) 60 (0.5) ,.001
Body mass index, kg/m2 26.2 (0.03) 28.4 (0.2) 26.9 (0.2) 29.3 (0.2) .02
Blood pressure, mm Hg
Systolic 140 (0.1) 152 (1.1) 150 (1.1) 155 (1.2) .02
Diastolic 82 (0.1) 87 (0.6) 86 (0.6) 88 (0.7) .007
Serum cholesterol, mmol/L‡ 6.1 (0.01) 6.2 (0.1) 6.3 (0.1) 6.2 (0.1) .001
*Data are given as age- and center-standardized mean (SE). DECODE indicates Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.
†To convert glucose to milligrams per deciliter, divide by 0.05551.
‡To convert cholesterol to milligrams per deciliter, divide by 0.02586.
Table 4. Multivariate-Adjusted Hazards Ratios for Deaths From Cardiovascular Disease (CVD), Coronary Heart Disease (CHD),
Stroke, and All Causes According to Fasting and 2-Hour Glucose Criteria: The DECODE Study*
Plasma (Whole Blood) Glucose Category, mmol/L [Subjects Not Known as Diabetic]
Known Diabetes‡
Fasting Glucose Criteria† 2-h Glucose Criteria‡
IFG 6.1-6.9 (5.6-6.0) Diabetes $7.0 (6.1) IGT 7.8-11.0 (6.7-9.9) Diabetes $11.1 (10.0)
Men
CVD 1.03 (0.85-1.25) 1.29 (0.98-1.71) 1.34 (1.12-1.60) 1.25 (0.92-1.70) 1.93 (1.53-2.44)
CHD 1.05 (0.80-1.37) 1.14 (0.77-1.68) 1.29 (1.02-1.64) 1.22 (0.82-1.81) 1.90 (1.41-2.57)
Stroke 0.89 (0.57-1.38) 1.64 (0.95-2.85) 1.26 (0.84-1.88) 1.37 (0.71-2.64) 2.08 (1.25-3.45)
All causes 1.10 (0.99-1.22) 1.62 (1.39-1.88) 1.42 (1.28-1.57) 1.83 (1.56-2.15) 1.76 (1.52-2.05)
Women
CVD 1.53 (0.81-2.90) 3.50 (1.89-6.47) 1.28 (0.88-1.86) 3.10 (1.87-5.15) 1.85 (1.30-2.63)
CHD 1.25 (0.39-4.03) 6.22 (2.97-13.01) 1.22 (0.69-2.15) 5.10 (2.66-9.79) 2.11 (1.27-3.48)
Stroke 3.02 (1.11-8.21) 4.57 (1.31-15.88) 1.21 (0.56-2.59) 3.30 (1.23-8.82) 1.05 (0.45-2.42)
All causes 1.20 (0.81-1.79) 2.01 (1.29-3.13) 1.25 (0.98-1.58) 2.25 (1.60-3.17) 1.88 (1.48-2.20)
All
CVD 1.09 (0.90-1.30) 1.48 (1.15-1.91) 1.34 (1.14-1.57) 1.55 (1.20-2.01) 1.96 (1.62-2.37)
CHD 1.07 (0.83-1.39) 1.43 (1.02-2.02) 1.28 (1.02-1.59) 1.64 (1.18-2.28) 1.94 (1.51-2.50)
Stroke 1.04 (0.70-1.56) 1.92 (1.16-3.17) 1.26 (0.88-1.79) 1.74 (1.01-2.99) 1.72 (1.11-2.66)
All causes 1.11 (1.00-1.23) 1.65 (1.43-1.91) 1.40 (1.27-1.54) 1.92 (1.66-2.22) 1.81 (1.60-2.05)
*Data are given as hazards ratios (95% confidence intervals), adjusted for age, center, total cholesterol, body mass index, systolic blood pressure, smoking,
and sex when men and women are combined (all). DECODE indicates Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe; IFG, impaired
fasting glucose; and IGT, impaired glucose tolerance.
†Using fasting plasma (whole blood) glucose ,6.1 (5.6) mmol/L as reference group. To convert glucose to milligrams per deciliter, divide by 0.05551.
‡Using 2-hour postload plasma (whole blood) glucose ,7.8 (6.7) mmol/L as reference group.
Table 5. Adjusted Hazards Ratios for Deaths From Cardiovascular Disease (CVD), Coronary Heart Disease (CHD), Stroke,
and All Causes With Fasting and 2-Hour Glucose Categories in the Same Model: The DECODE Study*
Mortality
Plasma (Whole Blood) Glucose Category, mmol/L [Subjects Not Known as Diabetic]
Known
Diabetes†
Fasting Glucose Criteria† 2-h Glucose Criteria‡
IFG 6.1-6.9 (5.6-6.0) Diabetes $7.0 (6.1) x2 (P )§ IGT 7.8-11.0 (6.7-9.9) Diabetes $11.1 (10.0) x2 (P )|
CVD 1.01 (0.84-1.22) 1.20 (0.88-1.64) 1.34 (..10) 1.32 (1.12-1.56) 1.40 (1.02-1.92) 12.09 (,.005) 1.96 (1.62-2.37)
CHD 1.01 (0.77-1.31) 1.09 (0.71-1.67) 0.15 (..10) 1.27 (1.01-1.58) 1.56 (1.03-2.36) 6.81 (,.05) 1.94 (1.51-2.50)
Stroke 1.00 (0.66-1.51) 1.64 (0.88-3.07) 2.35 (..10) 1.21 (0.84-1.74) 1.29 (0.66-2.54) 1.23 (..10) 1.73 (1.12-2.68)
All causes 1.03 (0.93-1.14) 1.21 (1.01-1.44) 4.32 (..10) 1.37 (1.25-1.51) 1.73 (1.45-2.06) 61.35 (,.001) 1.82 (1.60-2.06)
*Data are given as hazards ratios (95% confidence intervals), adjusted for age, sex, center, total cholesterol, body mass index, systolic blood pressure, and smoking.
DECODE indicates Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe; IFG, impaired fasting glucose; and IGT, impaired glucose tolerance.
†Using fasting plasma (whole blood) glucose ,6.1 (5.6) mmol/L as reference group. To convert glucose to milligrams per deciliter, divide by 0.05551.
‡Using 2-hour postload plasma (whole blood) glucose ,7.8 (6.7) mmol/L as reference group.
§Compared with the models in Table 4, with only the 2-hour glucose criteria, 2 df.
\Compared with the models in Table 4, with only the fasting glucose criteria, 2 df.
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Figure 1. Cumulative hazards curves for deaths from cardiovascular disease (CVD), coronary heart disease (CHD), stroke, and all causes, according to fasting and
2-hour glucose criteria. The cumulative hazards are estimated from Cox proportional hazards models and adjusted for age, center, sex, body mass index, blood
pressure, serum cholesterol levels, and smoking status. DM indicates diabetes mellitus; IFG, impaired fasting glucose; and NGT, normal glucose tolerance.
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consumption resulted in false elevated fasting glucose con-
centrations in some individuals, and these subjects might
have been misclassified as diabetic or IFG. However, the
fasting status must also have had an influence on 2-hour
glucose values because fasting and 2-hour glucose con-
centrations were correlated in subjects with higher fast-
ing glucose concentrations.3 Moreover, the excess risk
of CVD deaths observed among subjects with normal fast-
ing glucose levels but who were diabetic or IGT accord-
ing to the 2-hour glucose criteria could not be ex-
plained by the failure to fast.
The fasting glucose concentration has been consid-
ered to have good reproducibility, small variability, and
easy application in clinical practice. However, the fast-
ing state is difficult to assure in a population study,3 and
it has been found that fasting glucose level was not more
reliable than postload glucose level when measure-
ments were repeated in an elderly population.39 For epi-
demiological studies, the ADA did not recommend the
use of the 2-hour glucose measurement.1 However, in our
study, the 2-hour glucose value certainly gave addi-
tional prognostic information on the risk of death from
various causes. In our study, about one third of the men
(148 of 443) and 44% of the women (94 of 213) who were
diabetic according to the 2-hour glucose criteria were clas-
sified as normal according to the fasting glucose crite-
ria. These subjects carried a 50% higher risk for CVD mor-
tality and 100% higher risk for all-cause mortality
compared with subjects who had strictly normal levels
for both glucose criteria. The fact that inclusion of the
2-hour glucose with the fasting glucose criteria signifi-
cantly improved the prediction indicates that the pre-
dictive ability of the fasting glucose largely depended on
the levels of 2-hour glucose. Conversely, that fasting glu-
cose levels did not add statistically significant informa-
tion on the prediction of deaths once the 2-hour value
was included in the model demonstrated that the rela-
tion between the 2-hour glucose level and the risk of
deaths was independent of the fasting glucose levels.
A new category, IFG, based on fasting glucose level
alone was introduced by the ADA Expert Group.1 It was
claimed that IFG and IGT, based on the 2-hour glucose
concentration, were metabolic stages intermediate be-
tween normal glucose homeostasis and diabetes, and both
were risk factors for future diabetes and CVD. It is clear
from our study that people with IFG and IGT do not have
a similar prognosis with regard to CVD risk. We failed
to show any independent association of IFG with risk of
death from CVD and CHD; however, IFG was associ-
ated with stroke mortality in women. In contrast, the IGT
category based on the 2-hour glucose concentration pre-
dicted mortality from all causes, CVD, and CHD. The larg-
est number of excess CVD deaths was found in subjects
with IGT who had a normal fasting glucose level, which
also indicates that the IGT classification has prognostic
importance and cannot be replaced by IFG.
Diabetic women had a higher hazards ratio of death
from the CVD causes than the diabetic men, although the
difference in the hazards ratio between men and women
was statistically significant only for CHD mortality. This
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Figure 2. Estimated absolute number of excess cardiovascular deaths according to the duration of follow-up, with reference to the fasting and the 2-hour glucose
categories in subjects not previously known as diabetic. Number (n) and the total percentage of subjects in each glucose category are presented. To convert
glucose to milligrams per deciliter, divide by 0.05551.
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finding was compatible with women’s greater relative risk
of CVD associated with diabetes, as reported in other stud-
ies.40 In this study, age-standardized mortality from vari-
ous causes was higher in men than in women in each glu-
cose category, especially in the normal glucose category.
In men, the increase in mortality in the normal glucose
category reduced the relative risk of death observed in dia-
betic men and indicates that men are at higher risk of death
from risk factors other than hyperglycemia.
Age was an important confounding factor. It could
be argued that the excess risk of death in diabetic sub-
jects on the 2-hour glucose criteria could have been at-
tributed to the older age in this group. However, age has
been adjusted for in the data analyses, and the age dif-
ference was too small (only 2 years) to have any serious
impact on mortality. Other known CVD risk factors were
also taken into account and are unlikely to have influ-
enced the observed difference between the fasting and
the 2-hour glucose criteria.
In conclusion, diabetes and IGT determined by the
2-hour glucose criteria predicted mortality from the vari-
ous causes, independent of the level of fasting glucose,
whereas the association between mortality and diabetes
and IFG based on fasting glucose depended largely on
the 2-hour glucose categories. With regard to the pre-
diction of death, classification by 2-hour glucose con-
centration is better than that by fasting glucose.
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